Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

NCT02890368 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02890368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02890368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2016
Completion date
March 31, 2020
Enrollment
56 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, human papillomavirus-related malignant neoplasm, melanoma, merkel-cell carcinoma, mycosis fungoides, soft tissue sarcoma, solid tumors, squamous cell carcinoma